- Valeant (VRX) intends to its improve its $45.7B offer for Allergan (AGN) based of feedback that the Canadian company hopes to receive from Allergan shareholders during a Webcast about the deal on May 28.
- "We are prepared to pay a full and fair price, but, consistent with our track record, we will remain financially disciplined," Valeant said.
- The firm's comments come after Allergan formally rejected Valeant's proposal yesterday.
- Allergan's shares are +1.9% premarket. (PR)
From other sites
at MarketRealist.com (Mar 27, 2015)
at Zacks.com (Mar 25, 2015)
at Zacks.com (Mar 24, 2015)
at MarketRealist.com (Mar 23, 2015)
at Zacks.com (Mar 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs